Myasthenia gravis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 13
• BCMA 13
• CD20 3
• PD-1 0
• CD40 0
• JAK 0
• AKT 0
• HIF-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• AMPK 0
• AQP4 1
• COX-2 0
• GPX4 0
• HER2 0
• HMGB1 0
• IL-1 0
• IL-6 0
• MAPK 0
• NLRP3 0
• PD-L1 0
• PSMA 0
• SGLT2 0
• STAT3 0
• STING 0

24 of 573 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  REPROGRAMMING IMMUNITY FOR A BRIGHTER FUTURE FOR AUTOIMMUNE PATIENTS (ADCure)

  Canopy Immuno-Therapeutics Ltd· Megadim, Israel· EU contribution €2,430,249· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Understanding and targeting pathogenic IgG4 responses (IGG4-START)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €1,493,090· until Dec 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Systematic study of IgG4-autoimmune diseases to develop new treatment strategies (IgG4-TREAT)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €2,626,812· until Aug 2027· 9 countries

3 of 3 running projects, newest first. Listed amounts together: €6.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

  NCT07583030· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 2 Oct 2026

  “pipeline strategy change”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Terminated

  Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

  NCT05403541· Immunovant Sciences GmbH· Updated 14 Sept 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

  NCT06869278· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 24 Jun 2026

  “Legend discontinues the development of the IMP.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

  NCT06965309· Shenzhen MagicRNA Biotechnology Co., Ltd· Updated 12 Feb 2026

  “Change of registrant”Registry text, quoted unchanged. Source

• Terminated

  Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

  NCT04226170· DAS-MG, Inc· Updated 11 Sept 2025

  “lack of enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Oxaloacetate in Myasthenia Gravis

  NCT04965987· University of Kansas Medical Center· Updated 11 Jul 2025

  “No funding”Registry text, quoted unchanged. Source

• Withdrawn

  An Exploratory Clinical Study of GC012F Injection for Refractory gMG

  NCT06419166· Zhejiang University· Updated 27 Jun 2025

  “The study stopped early, before enrolling its first participant.”Registry text, quoted unchanged. Source

• Withdrawn

  A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

  NCT04224506· ProgenaBiome· Updated 5 Jun 2025

  “Company shifted focus”Registry text, quoted unchanged. Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Hoffmann-La Roche· Updated 28 Feb 2025

  “Sponsor decided to halt development of satralizumab in generalized myasthenia gravis and discontinued further dosing with the study drug (while the OLE period was ongoing) upon reviewing the primary results (DB period).”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

  NCT06540144· UCB Biopharma SRL· Source

• A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· UCB Biopharma SRL· Source

• A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· UCB Biopharma SRL· Source

• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

  NCT06055959· UCB Biopharma SRL· Source

• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Janssen Research & Development, LLC· Source

• A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

  NCT05265273· Janssen Research & Development, LLC· Source

• Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Janssen Research & Development, LLC· Source

• Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

  NCT07246564· UCB Biopharma SRL· Source

• Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis

  NCT06707727· First Affiliated Hospital of Chongqing Medical University· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 9
• Gene Expression Profiling 6
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 6
• Flow Cytometry 4
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 8
• Cohort Studies 37
• Genome-Wide Association Study 10

• Dropped head syndrome as the sole presenting manifestation of probable post-cytomegalovirus immune-mediated brainstem encephalitis in an immunocompetent woman: a case report.

  Front Immunol, Aug 2026

• Generalized thymoma-associated myasthenia gravis associated with anti-α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid receptor antibody encephalitis: A case report.

  Medicine (Baltimore), Aug 2026

• Immune Checkpoint Inhibitor-Associated Myocarditis: A Retrospective Case Series.

  Rom J Intern Med, Jun 2026

• Successful treatment of anti-LGI1-associated autoimmune encephalitis with efgartigimod: A case report and literature review.

  Medicine (Baltimore), May 2026

• Epstein-Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations.

  Viruses, Apr 2026

• Ophthalmoplegia Caused by Non-Aneurysm Neurovascular Conflict: Clinical Cases of Eight Patients.

  Rev Neurol, Mar 2026

• Isolated dysphagia masking myasthenia gravis diagnosis.

  Arq Neuropsiquiatr, Mar 2026

• Incidence and clinical characteristics of concurrent thyroid eye disease and ocular myasthenia gravis.

  Can J Ophthalmol, Feb 2026

• Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

  Front Immunol, Nov 2025

• Mills' syndrome and myasthenia gravis: a case report.

  Neuromuscul Disord, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.